Efficacy of PD-1 inhibitor combined with SOX regimen in the treatment of advanced gastric cancer and its influence on peripheral blood T lymphocyte subsets
Objective To analyze the efficacy of programmed death receptor-1(PD-1)inhibitor combined with SOX regi-men(temozolomide combined with oxaliplatin)in the treatment of advanced gastric cancer patients and its impact on the level of periph-eral blood T lymphocyte subsets.Methods The data of 90 patients with advanced gastric cancer were retrospectively analyzed.The pa-tients were divided into the control group(treated with SOX regimen)and the study group(treated with PD-1 inhibitor combined with SOX regimen)according to the different treatment plans,with 45 cases in each group.The clinical efficacy,quality of life measurement scale system of gastric cancer(QLICP-ST),Karnofsky Performance Status(KPS),and adverse reactions were compared between the two groups.The levels of serum tumor markers[carbohydrate antigen 724(CA724),pepsinogen Ⅰ(PG-Ⅰ),carcinoembryonic antigen(CEA)]and peripheral blood T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+)were compared between the two groups.Results The disease control rate of the study group(75.56％)was higher than that in the control group(55.56％)(P＜0.05).After treatment,QLICP-ST scores and KPS scores in the study group were higher than those in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions,such as nausea,vomiting,liver injury,constipation,diarrhea,bone marrow sup-pression,rash,itching,neurotoxicity and cardiac toxicity between the two groups(P＞0.05).After treatment,the PG-Ⅰ level in the stud-y group was higher than that in the control group,while the levels of CA724 and CEA were lower than those in the control group(P＜0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the study group were higher than those in the control group(P＜0.05).Conclusion PD-1 inhibitor combined with SOX regimen in the treatment of advanced gastric cancer can effectively control dis-ease progression,alleviate immune suppression,improve patients'physical status,enhance the quality of life,and have high safety.
Monocyte programmed death receptor-1 inhibitorsAdvanced gastric cancerSOX schemeT lymphocyte subsets
NETL
NSTL
万方数据
